Epaxal^®: a virosomal vaccine to prevent hepatitis A infection

References

• Hepatitis A: a vaccine at last. Lancet339(8803), 1198–1199 (1992).
   PubMed Web of Science ®Google Scholar
• Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA272(11), 885–889 (1994).
   PubMed Web of Science ®Google Scholar
• Bell BP, Anderson DA, Feinstone SM. Hepatitis A virus. In: Principles and Practices of Infectious Diseases. Mandell GL, Bennett JE, Dolin R (Eds). Elsevier Churchill Livingstone, PA, USA 2162–2185 (2005).
   Google Scholar
• Crowcroft NS, Walsh B, Davison KL, Gungabissoon U. Guidelines for the control of hepatitis A virus infection. Commun. Dis. Public Health4(3), 213–227 (2001).
   PubMedGoogle Scholar
• Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med.128(2), 111–114 (1998).
   PubMed Web of Science ®Google Scholar
• Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J. Infect. Dis.197(9), 1282–1288 (2008).
   PubMed Web of Science ®Google Scholar
• Forbes A, Williams R. Changing epidemiology and clinical aspects of hepatitis A. Br. Med. Bull.46(2), 303–318 (1990).
   PubMed Web of Science ®Google Scholar
• Melnick JL. History and epidemiology of hepatitis A virus. J Infect Dis.171(Suppl. 1), S2–S8 (1995).
   PubMed Web of Science ®Google Scholar
• Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics109(5), 839–845 (2002).
   PubMed Web of Science ®Google Scholar
• Dagan R, Leventhal A, Anis E, Slater P, Ashur Y, Shouval D. Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA294(2), 202–210 (2005).
   PubMed Web of Science ®Google Scholar
• Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA294(2), 194–201 (2005).
   PubMed Web of Science ®Google Scholar
• Dominguez A, Oviedo M, Carmona G et al. Impact and effectiveness of a mass hepatitis A vaccination programme of preadolescents seven years after introduction. Vaccine26(14), 1737–1741 (2008).
   PubMed Web of Science ®Google Scholar
• Hanna JN, Hills SL, Humphreys JL. Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med. J. Australia181(9), 482–485 (2004).
   PubMed Web of Science ®Google Scholar
• Lopalco PL, Prato R, Chironna M, Germinario C, Quarto M. Control of hepatitis A by universal vaccination of adolescents, Puglia, Italy. Emerg. Infect. Dis.14(3), 526–528 (2008).
   PubMed Web of Science ®Google Scholar
• Averhoff F, Shapiro CN, Bell BP et al. Control of hepatitis A through routine vaccination of children. JAMA286(23), 2968–2973 (2001).
   PubMed Web of Science ®Google Scholar
• Germinario C, Lopalco PL, Chirona M, Da Villa G. From hepatitis B to hepatitis A and B prevention: the Puglia (Italy) experience. Vaccine18(Suppl. 1), S83–S85 (2000).
   PubMed Web of Science ®Google Scholar
• McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch. Pediatr. Adolesc. Med.150(7), 733–739 (1996).
   PubMed Web of Science ®Google Scholar
• Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep.55(RR-7), 1–23 (2006).
   PubMedGoogle Scholar
• Koff RS. Hepatitis A. Lancet351(9116), 1643–1649 (1998).
   PubMed Web of Science ®Google Scholar
• Wiedermann G, Ambrosch F, Kollaritsch H et al. Safety and immunogenicity of an inactivated hepatitis A candidate vaccine in healthy adult volunteers. Vaccine8(6), 581–584 (1990).
   PubMed Web of Science ®Google Scholar
• Wang XY, Xu Z, Yao X et al. Immune responses of anti-HAV in children vaccinated with live attenuated and inactivated hepatitis A vaccines. Vaccine22(15–16), 1941–1945 (2004).
   PubMed Web of Science ®Google Scholar
• Gluck R. Adjuvant activity of immunopotentiating reconstituted influenza virosomes (IRIVs). Vaccine17(13–14), 1782–1787 (1999).
   PubMed Web of Science ®Google Scholar
• Gluck R, Metcalfe IC. New technology platforms in the development of vaccines for the future. Vaccine20(Suppl. 5), B10–B16 (2002).
   PubMed Web of Science ®Google Scholar
• Gluck R, Walti E. Biophysical validation of Epaxal Berna, a hepatitis A vaccine adjuvanted with immunopotentiating reconstituted influenza virosomes (IRIV). Dev. Biol. (Basel)103, 189–197 (2000).
   PubMedGoogle Scholar
• Gluck R, Moser C, Metcalfe IC. Influenza virosomes as an efficient system for adjuvanted vaccine delivery. Expert Opin. Biol. Ther.4(7), 1139–1145 (2004).
   PubMed Web of Science ®Google Scholar
• Moser C, Metcalfe IC, Viret JF. Virosomal adjuvanted antigen delivery systems. Expert Rev. Vaccines2(2), 189–196 (2003).
   PubMedGoogle Scholar
• Bungener L, Serre K, Bijl L et al. Virosome-mediated delivery of protein antigens to dendritic cells. Vaccine20(17–18), 2287–2295 (2002).
   PubMed Web of Science ®Google Scholar
• Bungener L, Huckriede A, de Mare A, de Vries-Idema J, Wilschut J, Daemen T. Virosome-mediated delivery of protein antigens in vivo: efficient induction of class I MHC-restricted cytotoxic T lymphocyte activity. Vaccine23(10), 1232–1241 (2005).
   PubMed Web of Science ®Google Scholar
• D’Acremont V, Herzog C, Genton B. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in the elderly. J. Travel Med.13(2), 78–83 (2006).
   PubMed Web of Science ®Google Scholar
• Genton B, D’Acremont V, Furrer HJ, Hatz C, Louis L. Hepatitis A vaccines and the elderly. Travel Med. Infect. Dis.4(6), 303–312 (2006).
   PubMedGoogle Scholar
• Usonis V, Bakasenas V, Valentelis R, Katiliene G, Vidzeniene D, Herzog C. Antibody titres after primary and booster vaccination of infants and young children with a virosomal hepatitis A vaccine (Epaxal). Vaccine21(31), 4588–4592 (2003).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Mijalovsky A et al. Immunization against hepatitis A in the first year of life: priming despite the presence of maternal antibody. Pediatr. Infect. Dis. J.19(11), 1045–1052 (2000).
   PubMed Web of Science ®Google Scholar
• Bovier PA, Althaus B, Glueck R, Chippaux A, Loutan L. Tolerance and immunogenicity of the simultaneous administration of virosome hepatitis A and yellow fever vaccines. J. Travel Med.6(4), 228–233 (1999).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Finkel B, Herzog C, Koren A, Kollaritsch H. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine. Infection32(3), 149–152 (2004).
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Tieamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ Jr. Control of a hepatitis A outbreak by active immunization of high-risk susceptible subjects. J. Infect. Dis.169(1), 228–229 (1994).
   PubMed Web of Science ®Google Scholar
• Mayorga Perez O, Herzog C, Zellmeyer M, Loaisiga A, Frosner G, Egger M. Efficacy of virosome hepatitis A vaccine in young children in Nicaragua: randomized placebo-controlled trial. J. Infect. Dis.188(5), 671–677 (2003).
   PubMed Web of Science ®Google Scholar
• Innis BL, Snitbhan R, Kunasol P et al. Protection against hepatitis A by an inactivated vaccine. JAMA271(17), 1328–1334 (1994).
   PubMed Web of Science ®Google Scholar
• Werzberger A, Mensch B, Kuter B et al. A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children. N. Engl. J. Med.327(7), 453–457 (1992).
   PubMed Web of Science ®Google Scholar
• Dagan R, Amir J, Livni G et al. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial. Pediatr. Infect. Dis. J.26(9), 787–793 (2007).
   PubMed Web of Science ®Google Scholar
• Pancharoen C, Mekmullica J, Thisyakorn U, Kasempimolporn S, Wilde H, Herzog C. Reduced-dose intradermal vaccination against hepatitis A with an aluminum-free vaccine is immunogenic and can lower costs. Clin. Infect. Dis.41(10), 1537–1540 (2005).
   PubMed Web of Science ®Google Scholar
• Van Der Wielen M, Vertruyen A, Froesner G et al. Immunogenicity and safety of a pediatric dose of a virosome-adjuvanted hepatitis A vaccine: a controlled trial in children aged 1–16 years. Pediatr. Infect. Dis. J.26(8), 705–710 (2007).
   PubMed Web of Science ®Google Scholar
• Holzer BR, Hatz C, Schmidt-Sissolak D, Gluck R, Althaus B, Egger M. Immunogenicity and adverse effects of inactivated virosome versus alum-adsorbed hepatitis A vaccine: a randomized controlled trial. Vaccine14(10), 982–986 (1996).
   PubMed Web of Science ®Google Scholar
• Bovier PA, Farinelli T, Loutan L. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine. Vaccine23(19), 2424–2429 (2005).
   PubMed Web of Science ®Google Scholar
• Clarke PD, Adams P, Ibanez R, Herzog C. Rate, intensity, and duration of local reactions to a virosome-adjuvanted vs. an aluminium-adsorbed hepatitis A vaccine in UK travellers. Travel Med. Infect. Dis.4(6), 313–318 (2006).
   PubMedGoogle Scholar
• Beck BR, Hatz CF, Loutan L, Steffen R. Immunogenicity of booster vaccination with a virosomal hepatitis A vaccine after primary immunization with an aluminum-adsorbed hepatitis A vaccine. J. Travel Med.11(4), 201–206 (2004).
   PubMed Web of Science ®Google Scholar
• Beck BR, Hatz C, Bronnimann R, Herzog C. Successful booster antibody response up to 54 months after single primary vaccination with virosome-formulated, aluminum-free hepatitis A vaccine. Clin. Infect. Dis.37(9), e126–128 (2003).
   PubMed Web of Science ®Google Scholar
• van der Ploeg R, Beck BR, Froesner G, Hunt M, Herzog C, Hatz C. Successful booster response 8 to 11 years after a single primary vaccination with a virosome-formulated hepatitis A vaccine (Epaxal). Presented at: Proceedings of the 10th CISTM. Vancouver, Canada (2007).
   Google Scholar
• Bovier PA, Bock J, Loutan L, Farinelli T, Glueck R, Herzog C. Long-term immunogenicity of an inactivated virosome hepatitis A vaccine. J. Med. Virol.68(4), 489–493 (2002).
   PubMed Web of Science ®Google Scholar
• Van Damme P, Banatvala J, Fay O et al. Hepatitis A booster vaccination: is there a need? Lancet362(9389), 1065–1071 (2003).
   PubMed Web of Science ®Google Scholar
• Mengiardi B, Berger R, Just M, Gluck R. Virosomes as carriers for combined vaccines. Vaccine13(14), 1306–1315 (1995).
   PubMed Web of Science ®Google Scholar
• Pregliasco F, Mensi C, Serpilli W, Speccher L, Masella P, Belloni A. Immunogenicity and safety of three commercial influenza vaccines in institutionalized elderly. Aging (Milano)13(1), 38–43 (2001).
   PubMedGoogle Scholar
• Zuccotti G, Amendola A, Vigano A et al. Long-term immunogenicity of a virosomal subunit inactivated influenza vaccine in children with asthma. Vaccine25(37–38), 6692–6698 (2007).
   PubMed Web of Science ®Google Scholar
• Ellis A, Ruttimann RW, Jacobs RJ, Meyerhoff AS, Innis BL. Cost–effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev. Panam. Salud Publica21(6), 345–356 (2007).
   PubMed Web of Science ®Google Scholar
• Poovorawan Y, Theamboonlers A, Chumdermpadetsuk S, Gluck R, Cryz SJ Jr. Safety, immunogenicity, and kinetics of the immune response to a single dose of virosome-formulated hepatitis A vaccine in Thais. Vaccine13(10), 891–893 (1995).
   PubMed Web of Science ®Google Scholar
• Ambrosch F, Wiedermann G, Jonas S et al. Immunogenicity and protectivity of a new liposomal hepatitis A vaccine. Vaccine15(11), 1209–1213 (1997).
   PubMed Web of Science ®Google Scholar
• Riedemann S, Reinhardt G, Ibarra H, Frosner GG. Immunogenicity and safety of a virosomal hepatitis A vaccine (Epaxal) in healthy toddlers and children in Chile. Acta Paediatr.93(3), 412–414 (2004).
   PubMed Web of Science ®Google Scholar
• Loutan L, Bovier P, Althaus B, Gluck R. Inactivated virosome hepatitis A vaccine. Lancet343(8893), 322–324 (1994).
   PubMed Web of Science ®Google Scholar
• Just M, Berger R, Dreschsler H, Brantschen S, Gluck R. A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks. Vaccine10(11), 737–739 (1992).
   PubMed Web of Science ®Google Scholar